Sidvim LifeSciences Private Limited

  Contents Patent applications filed by Suven Life Sciences General information Piramal upgrading UK sites Molnupiravir supplies dominate in times of Paxlovid scarcity Intellectual Property T 1131/18 (Combination of Pimobendan and Benazepril/ ELANCO) of 19.10.2021 Patent applications filed by Suven Life Sciences  We analyse patent filings by many Indian companies. This week analysed patent portfolio of Suven Life Sciences for last 2-3 years. Most of the applications are filed for their proprietary molecules, which are in different stages of clinical studies. Here .  From IP portfolio, it seems masupirdine and abiraterone acetate/derivatives are the most interesting candidates.  Publication Number Abstract  Publication Date SIDVIM comments WO2021111330A1 A method for treating behavioural and psychological symptoms in patient with dementia comprising administering an effective dose of pure 5-HT 6 receptor antagonist, masupirdine or a pharmaceutically acceptable salt thereof. 

  Contents DMF filings in December 2022 General information Huge stock of oxytocin drug seized from New Delhi station PIC/S revises GMP guide to reflect new EU clinical trials regulation Intellectual Property Neurim v. Mylan DMF filings in December 2022 We analyze DMF filings of Indian companies. This month, we analyzed DMFs filed in December 2021.  Glimpses of our analysis are as below.  HOLDER SUBJECT SIDVIM comments SUN PHARMACEUTICAL INDUSTRIES LTD LIRAGLUTIDE Liraglutide will become generic in early 2023 in US. Teva as per settlement with Brand, would be able to launch in December 2022. Sun perhaps would launch in the second phase, along with many others. BIOPHORE INDIA PHARMACEUTICALS PVT LTD INDOCYANINE GREEN Indocyanine green is a cyanine dye used in medical diagnostics. It is used for determining cardiac output, hepatic function, liver and gastric blood flow, and for ophthalmic angiography.  Only one other DMF. Very smart molecule selection by Biophore. BIOPHORE INDI

  Contents DMF filings in November 2022 General information North America is seeing a hiring boom in pharmaceutical industry ESG roles Pharma industry wants Budget to announce incentives for conducting R&D Intellectual Property T 1133/18 (Sublingual apomorphine/SUNOVION) of 15.12.2021 DMF filings in November 2022 We analyze DMF filings of Indian companies. Couple of weeks ago we analyzed DMF filings in the month of October 2021 and this week we have analyzed DMF filed in the month of November 2022. About 50 DMFs filed in November and more than 50% of those are from Indian API suppliers.  Glimpses of our analysis is as below.  HOLDER SUBJECT SIDVIM comments DR REDDYS LABORATORIES LTD ERIBULIN MESYLATE DRL owns IP the process of eribulin, different fractions combined to manufacture eribulin. Earlier DRL filed DMF for one of the fractions, fraction A and now filed DMF for eribulin. This will become generic in 2022, and one could see few DMFs soon. Nevertheless, very comple